10.22.26 -- Is Your Manufacturing Process Ready For MES?

This collaboration demonstrates how a partnership-driven approach, combined with technical expertise, can deliver scalable, efficient, and reliable manufacturing solutions that support successful global commercialization.

Metal-sensitive analytes often suffer from poor recovery and distorted peak shapes. Learn how inert hardware improves sensitivity and chromatographic performance for challenging analyses.

As AAV manufacturing matures, integrated optimization of capture, buffer chemistry, load conditioning, and AEX polishing enables scalable full capsid enrichment, improving product quality and manufacturability.

A systematic evaluation of an end-to-end cryopreserved CAR-T workflow examines how critical process parameters and unit operation interdependencies affect manufacturing consistency and robustness.

Engineering decisions in fill/finish directly shape product quality and sterility assurance. This article examines how inert gas purging, plunger placement, dosing verification, and barrier systems interact across line design.

Evaluating single-use bioprocess modalities requires aligning capital strategy, standardized extractables frameworks, and updated biocompatibility testing to ensure compliance.

Gain a foundational understanding of the process for culturing mesenchymal stem cells in stirred-tank bioreactors and learn about the key parameters for successful scale-up.

Observe how streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.

A new chemically defined fed-batch bioprocess medium simplifies hMSC-EV production, increasing yields by 2-4x while maintaining EV quality across donors and tissue types in scalable GMP-compatible environments.

Explore strategies for scaling MSC manufacturing while mitigating biological and operational risks. Learn how closed-system platforms and optimized workflows accelerate the path to commercial cell therapy.

Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

Space constraints and sterile integrity drive the shift toward modular, robotic manufacturing. Discover how adopting compact, automated systems reduces energy overhead and contamination risks.

Uncover how a unique partnership model helps cell and gene therapy developers accelerate progress, reduce risk, and bring transformative therapies to market faster.

Choosing the right incubator requires more than reading specs. Learn how to evaluate performance metrics, contamination control, and real-world functionality to make confident equipment decisions.

Explore how CD83-targeted CAR T cells may address a central challenge in AML treatment by suppressing malignant blasts while sparing healthy progenitor cells, with insights into antigen biology.